Is Treatment of Insulin Resistance Beneficial Independent of Glycemia?

Diabetes Care

Volumn 26, Issue 11, 2003, Pages 3184-3186

  Davidson, Mayer B ^a  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; EDITORIAL; GLUCOSE BLOOD LEVEL; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; RISK FACTORS;

EID: 0242363723     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.11.3184     Document Type: Editorial

References (39)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment PaneI III). JAMA 285:2486-2509, 2001
2. Alberti KGMM, Zimmet PZ, the WHO Consultation: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 15:539-553, 1998
3. Simpson RW, Shaw JE, Zimmet PZ: The prevention of type 2 diabetes: life style change or pharmacotherapy? A challenge for the 21st century. Diabetes Res Clin Pract 59:165-180, 2003
4. Meigs JB, Nathan DM, D'Agostino RB, Wilson PWF: Fasting and post-challenge glycemia and cardiovascular risk: the Framingham Offspring Study. Diabetes Care 25:1845-1850, 2002
5. Stern MP, Fatehi P, Williams K, Haffner SM: Predicting cardiovascular disease: do we need the oral glucose tolerance test? Diabetes Care 25:1851-1856, 2002
6. Pan X-R, Li G-W, Hu Y-H, Wang J-X, Yang W-Y, An Z-X, Hu Z-X, Lin J, Xioa, J-Z, Cao H-B, Liu P-A, Jiang X-G, Jiang Y-Y, Wang J-P, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
7. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laako M, Louheranta A, Rastas M, Salminen V, Uusitupa M, the Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
8. The Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
9. Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, Berra K, Blair SN, Costa F, Franklin B, Fletcher GF, Gordon NF, Pate RR, Rodriguez BL, Yancey AK, Wenger NK: Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the council on clinical cardiology (subcommittee on exercise, rehabilitation, and prevention) and the council on nutrition, physical activity, and metabolism (subcommittee on physical activity). Circulation 107:3109-3116, 2003
10. Montague CT, O'Rahilly SO: The perils of portliness: causes and consequences of visceral adiposity. Diabetes 49:883-888, 2000
11. Facchini FS, Hua N, Abbasi F, Reaven GM: Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 86:3574-3578, 2001
12. Shadid S, Jenson MD: Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 26:3148-3152, 2003
13. Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW, the Troglitazone Study Group: Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. J Clin Endocrinol Metab 83:3169-3176, 1998
14. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI, the Rosiglitazone Clinical Trials Group: Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86:280-288, 2001
15. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL, the Pioglitazone 001 Study Group: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 23:1605-1611, 2000
16. Tack CJJ, Smits P, Demacker PNM, Stalenhoff AFH: Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 21:796-799, 1998
17. Freed MI, Marcovina SM, Kreider MM, Biswas N, Brunzell JD: Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 90:947-952, 2002
18. Winkler K, Konrad T, Füllert S, Friedrich I, Destani R, Baumstark MW, Krebs K, Weiland H, März W: Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care 26:2588-2594, 2003
19. Raji A, Seely EA, Bekins SA, Willians GH, Simonson DC: Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 26:172-178, 2003
20. Fonseca VA, Reynolds T, Hemphill D, Randolph C, Wall J, Valiquet TR, Graveline J, Fink LM: Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 12:181-186, 1998
21. Ghanim H, Garg R, Aljada A, Mohanty P, Kumbkarni Y, Assian E, Hamouda W, Dandona P: Suppression of nuclear factor-kB and stimulation of inhibitor kB by troglitazone: evidence for an antiinflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 86:1306-1312, 2001
22. Aljada A, Garg R, Ghanim H, Mohanty P Houmada W, Assian E, Dandona P: Nuclear factor-kB suppressive and inhititor-kB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflamlmatory action? J Clin Endocrinol Metab 86:3250-3256, 2001
23. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679-684, 2002
24. Satoh N, Ogawa Y, Usui T, Tagami T, Kohno S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H, Nakao K: Antiatherogenic effect of pioglitazone in type 2 diabetic patients, irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26:2493-2499, 2003
25. Lusis A: Atherosclerosis. Nature 407:233-241, 2000
26. Cominacini L, Garbin U, Pasini AF. Campagnola M, Davoli A, Foot E, Sigheiri G, Sironi AM, Cascio VL, Ferrannini E: Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes 47:130-133, 1998
27. Agrawal A, Chen H, Yan Y, Mather R, Albertini J-P, Valensi P, Hanefeld M: Rosiglitazone improves postprandial glycemia and markers of endothelial function in patients with type 2 diabetes (Abstract). Diabetes 51 (Suppl. 2):A92, 2002
28. Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Scharnagl H, Hombach V, Koenig W: Antidiabetic PPAR-gamma activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 23:283-288, 2003
29. Wofford JL, Kahl FR, Howard GR, McKinney WM, Toole JF, Crouse JR 3rd: Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. Arterioscler Thromb 11:1786-1794, 1991
30. Minikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83:1818-1820, 1998
31. Koshiyasma H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86:3452-3456, 2001
32. Cabellero AE, Saouaf R, Lim SC, Hamdy O, Abou-Elenin K, O'Connor C, LoGerfo FW, Horton ES, Veves A: The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 52:173-180, 2003
33. Natali A, Baldeweg S, Toschi E, Barbaro D, Capaldo B, Yudkin J, Ferrannini E: Rosiglitazone directly improves endothelial function in type 2 diabetic patients (Abstract). Diabetes 51 (Suppl. 2):A142, 2002
34. Taniwaki H, Kanda H, Kawagishi T, Maekawa K, Emoto M, Nishizawa Y, Shoji T, Morii H: Correlation between the intima-media thickness of the carotid artery and aortic pulse-wave velocity in patients with type 2 diabetes: vessel wall properties in type 2 diabetes. Diabetes Care 22:1851-1857, 1999
35. Cohn JN: Vascular wall function as a risk marker for cardiovascular disease. J Hypertens 17:S41-S44, 1999
36. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG: Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 106:2085-2090, 2002
37. Plummer EV, Lawson M, Domb A, Chen K, Gerkin R, Reaven PD: Effects of treatment with rosiglitazone on myocoardial blood flow (MBF) in type 2 diabetes (DM2) (Abstract). Diabetes 51 (Suppl. 2): A161, 2002
38. Choi SH, Choi DH, Ko YK, Chang YS, Cho YL, Lim SK, Nam M-S, Lee HC, Cha BS: Preventive effects of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes (Abstract). Diabetes 52 (Suppl. 1):A19, 2003
39. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, Ibuki M, Tani T, Tanabe K, Nagai K, Shiratori K, Morioka S, Yoshikawa J: Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study (Abtract). Am Heart J 146:E5, 2003